



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/715,902	11/17/2000	John James Donnelly	1627.003	5612
27476	7590	05/05/2009	EXAMINER	
NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY R338 P.O. BOX 8097 Emeryville, CA 94662-8097			WEHBE, ANNE MARIE SABRINA	
			ART UNIT	PAPER NUMBER
			1633	
			MAIL DATE	DELIVERY MODE
			05/05/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	09/715,902	DONNELLY ET AL.
	Examiner	Art Unit
	Anne Marie S. Wehbe	1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 11 February 2009.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-9, 11-16, 18-23, 29-31, 33-44, 46, 50 and 52-59 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-9, 11-16, 18-23, 29-31, 33-44, 46, 50 and 52-54 is/are rejected.

7) Claim(s) 55-59 is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____ .	6) <input type="checkbox"/> Other: _____ .

DETAILED ACTION

A request for continued examination (RCE) under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 2/11/09 has been entered.

Applicant's amendment and response filed with the RCE have been entered. Claims 10, 17, 24-28, 32, 45, 47-49, and 51 are canceled and new claims 55-59 have been added. Claims 1-9, 11-16, 18-23, 29-31, 33-44, 46, 50, and 52-54 are currently pending and under examination in the instant application. An action on the merits follows.

Claim Rejections - 35 USC § 103

The rejection of previously pending claims 1-16, 18-23, 29-31, 33-44, 46, 50, and 52-54 under 35 U.S.C. 103(a) as being unpatentable over WO 97/24447 (7/10/97), hereafter referred to as Song et al., in view of US Patent No. 5,783,567 (7/21/98), hereafter referred to as Hedley et al., and further in view of Fattal et al. (1998) J. Controlled Rel., Vol. 53, 137-143, is withdrawn over canceled claim 10, and maintained over pending claims 1-9, 11-16, 18-23, 29-31, 33-44, 46, 50, and 52-54. The remaining claims have not been amended. Applicant's arguments have been

fully considered but have not been found persuasive in overcoming the rejection for reasons of record as discussed in detail below.

The applicant has split their response to the rejection into three parts. The applicant has chosen to provide separate argument sections for 1) claim 54, 2) claims 1-16, 18-23, 29-31, 33-34, 46, 50, and 52-53, and 3) claims 19-23. However, please note that claims 19-23 have been argued twice in separate sections. These arguments are addressed in order.

1) The applicant reiterates arguments presented in the appeal brief of 5/17/07 that claim 54 is non-obvious and alleges that the rejection of record is based on improper hindsight reasoning, citing MPEP 2141-2142, *In re Vaeck and Hodosh v. Block Drug Co., Inc.* The applicant then points out what, in applicant's opinion, are the deficiencies in each reference that precludes their combination.

To begin, it is noted that the test for combining references is not what the individual references themselves suggest, but rather what the combination of disclosures taken as a whole would have suggested to one of ordinary skill in the art. *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). For the purpose of combining references, those references need not explicitly suggest combining teachings, much less specific references. *In re Nilssen*, 7 USPQ2d 1500 (Fed. Cir. 1988). Furthermore, it is well established in case law that a reference must be considered not only for what it expressly teaches, but also for what it fairly suggests. *In re Burkel*, 201 USPQ 67 (CCPA 1979). In the determination of obviousness, the state of the art as well as the level of skill of those in the art are important factors to be considered. The teaching of the cited references must be viewed in light of these factors. Most importantly, obviousness does **not** require absolute predictability of success; for obviousness under 35 U.S.C. 103, all that

is required is a reasonable expectation of success. See *In re O'Farrell*, 7 USPQ2d 1673 (CAFC 1988). Further, in response to Applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the Applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971).

The Applicant acknowledges that Song et al. teaches several gene delivery vehicles for gene delivery to dendritic cells, but argues that Song et al. does not teach a transfection agent comprising a polynucleotide and a microparticle as claimed, and that Song et al. demonstrates a preference for recombinant retroviral techniques over non-viral techniques. The Applicant further argues that neither Hedley et al. nor Fattal et al. overcome this deficiency in Song. As such, the Applicant concludes that Song et al. in combination with the other cited references would only provide motivation for using recombinant retroviruses for *in vivo* transfection of dendritic cells. In response, Song et al. teaches methods of transfecting dendritic cells *ex vivo* or *in vitro* with a gene delivery vehicle comprising DNA encoding an antigen such as a tumor antigen or HIV antigen, and use of said transfected dendritic cells to induce an immune response against the expressed antigen *in vivo* (Song et al., pages 2, 3, and 18-20). Regarding gene delivery vehicles taught by Song et al., Song teaches that for *ex vivo/in vitro* transfection of dendritic cells, both non-viral and viral gene delivery vehicles can be used, including the use of expression vectors complexed with polycations or lipids, or encapsulated in liposomes (Song et

al., page 1, and pages 14-19). Thus, Song et al. teaches that numerous gene delivery vehicles can be successfully utilized to transfect dendritic cells including the use of plasmid/liposomes, and plasmid combined with cationic condensing agents. The fact that Song et al. exemplified retroviral transduction of dendritic cells does not invalidate the clear teachings in this reference that many techniques, including non-viral techniques, can be used to transfect dendritic cells *in vitro*. According to the Applicants, the fact that Song et al. exemplified retroviruses teaches away from using non-viral vectors. However, this is not a fair reading of Song et al., as Song et al. clearly teaches the use of other delivery vectors, specifically non-viral vectors. Again, a reference must be considered not only for what it expressly teaches, but also for what it fairly suggests. *In re Burkel*, 201 USPQ 67 (CCPA 1979). Further, the applicant is directed to *In re Susi* and *In re Gurley*, which state respectively: that disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments. *In re Susi*, 440 F.2d 442, 169 USPQ 423 (CCPA 1971); and, "A known or obvious composition does not become patentable simply because it has been described as somewhat inferior to some other product for the same use." *In re Gurley*, 27 F.3d 551, 554, 31 USPQ2d 1130, 1132 (Fed. Cir. 1994). Thus, the office does not find that Song et al. teaches away from using non-viral vectors simply because they exemplified the use of the retroviral vectors rather than the use of the disclosed non-viral vectors. Furthermore, the Applicant is reminded that claim 54 as written, does not place any limitation on the nature of the polynucleotide and reads on the use of any polynucleotide including a retroviral polynucleotide.

In regards to Applicant's argument that Song et al. does not teach the use of microparticles, it is noted that Hedley et al. and Fattal et al. have been cited to supplement the

teachings of Song et al. Regarding the teachings of Hedley et al., the Applicant argues that Hedley primarily teaches the use of microparticles to transfect macrophages and that the only motivation for transfecting dendritic cells lies in *in vivo* rather than *in vitro/ex vivo* techniques. The applicant therefore concludes that the Office has engaged in improper hindsight reasoning to construct the rejection of record. In response, Hedley et al. has been cited for the use of microspheres comprising biodegradable polymers and DNA plasmids to introduce and express antigens encoded by the plasmids in antigen presenting cells such as macrophages and dendritic cells both *in vitro* and *in vivo* for the purpose of stimulating antigen specific immune responses (Hedley et al., columns 2-3 and 7-8). The fact that Hedley et al. teaches that transfection can take place *in vivo*, does not teach away from the clear suggestion to transfect cells *in vitro/ex vivo* taught by Hedley et al. in column 12. Hedley et al. further provides motivation for introducing plasmid DNA encoding an antigen to dendritic cells and macrophages using biodegradable microspheres by teaching that DNA combined with biodegradable microparticles is efficiently phagocytosed by antigen presenting cells (APCs) and is an effective means for introducing nucleic acids into these cells (Hedley et al., column 8, lines 13-49). While Hedley exemplifies the transfection of macrophages, the teachings of Hedley et al. are not so limited. Hedley et al. clearly teaches the transfection of APCs. Dendritic cells were well known at the time of filing as antigen presenting cells, as evidenced by Song et al. Further, Hedley et al. recognizes that dendritic cells are a legitimate target for the disclosed microparticle transfection when they state that the point of introduction of plasmid/microparticles to skin is the transfection of dendritic cells. Motivation for transfecting dendritic *ex vivo/in vitro* is derived primarily from the teachings of the primary reference, Song et al., who clearly teach and provide motivation for

transfected dendritic cells *ex vivo*, see above. However, Hedley et al. also teaches *ex vivo* transfection. In column 12, lines 23-30, Hedley et al. clearly states, "For *in vitro/ex vivo* use, the suspension of microparticles can be added either to cultured adherent mammalian cells or to a cell suspension". Thus, Hedley et al. clearly contemplates and teaches *ex vivo* transfection of APCs. This teaching is not limited to macrophages and includes other types of antigen presenting cells such as dendritic cells. Again, Song et al. already teaches the transfection of dendritic cells, Hedley is cited to provide motivation for using microparticles as a transfection agent. Thus, Applicant's arguments that Hedley et al. only provide motivation for *in vivo* transfection of dendritic cells is not found persuasive.

The applicant further provides a new argument that while macrophages were known to be aggressively phagocytic, dendritic cells were not, citing Lipscomb et al. (2002) and Karhumaki et al. (1993), provided with the instant response. According to applicant, since macrophages were known to be strongly phagocytic compared to dendritic cells and Hedley et al. exemplified macrophages, there would be no expectation of success that dendritic cells would be used to phagocytose the claimed microparticles. In response, Lipscomb et al. is a post-filing review article. In so far as it reflects what was known at the time of filing, circa November 1999, Lipscomb et al. teaches that in fact immature dendritic cells are avidly endocytic and that dendritic cells take up antigens, including whole cells, by phagocytosis, by receptor-mediated pinocytosis, and by fluid phase pinocytosis (Lipscomb et al., page 104). The fact that macrophages can be separated from macrophages based on phagocytosis as indicated by both Lipscomb and Karhumaki et al. does not change the fact that dendritic cells are in fact both phagocytic and endocytic. Thus, it is not agreed that the skilled artisan would not have

reasonably expected dendritic cells to be capable of taking up DNA or RNA microparticles. Further, as noted above, Hedley et al. clearly contemplated dendritic cells as a valid candidate antigen presenting cell for microparticle mediated transfection and Song et al., the primary reference, specifically teaches transfection of dendritic cells. Thus, one of skill in the art reading the teachings of both Song et al. and Hedley et al. would have had a reasonable expectation that dendritic cells would be capable of taking up DNA or RNA microparticles.

Regarding the claim that improper hindsight has been used to construct the instant rejection, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the Applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Furthermore, although applicant has stated, "...it is a well settled tenant of patent law that '[t]he references must be considered as a whole and must suggest the desirability and thus the obviousness of making the combination'. MPEP 2141, citing *Hodosh v. BlockDrug Co., Inc.*, 786 F.2d 1136, 1143 n.5,229 USPQ 182, 187 n.5 (Fed. Cir. 1986). (Emphasis added.)", it is noted that MPEP 2141 has been updated to reflect the U.S. Supreme Court decision in *KSR International Co. v. Teleflex Inc. (KSR)*, 550 U.S. ___, 82 USPQ2d 1385 (2007). MPEP 2141 now states that in part the KSR decision found that the Federal Courts had erred by overemphasizing "the risk of courts and patent examiners falling prey to hindsight bias" and as a result applying "[r]igid preventative rules that deny factfinders recourse to common sense" (Id.). Further, as discussed in detail above, improper hindsight was not used as Hedley et al. clearly

contemplates and teaches *ex vivo* transfection of APCs. This teaching is not limited to macrophages and includes other types of antigen presenting cells such as dendritic cells, and Song et al. already teaches and provides specific motivation for *ex vivo/in vitro* transfection of dendritic cells.

The applicant then argues that Hedley et al. teaches microparticles with internal nucleic acids rather than microparticles with adsorbed polynucleotides as claimed in claim 54. In response, Fattal et al. was cited to supplement the teachings of Hedley et al. by providing motivation for including a cationic detergent in the microparticles. Regarding encapsulation versus adsorption, please note that claim independent 54, like independent claim 1, are both broad and encompass microparticles with both adsorbed and encapsulated nucleic acids. While applicant has argued that it is irrelevant what the claims might encompass since there must be a teaching or motivation present in the prior art to make a conclusion of obviousness, MPEP 2141 states that the first step in determining obviousness is a determination of the scope of the claimed invention. MPEP 2141, “[t]he scope of the claimed invention must be clearly determined by giving the claims the ‘broadest reasonable interpretation consistent with the specification.’ See *Phillips v. AWH Corp.*, 415 F.3d 1303, 1316, 75 USPQ2d 1321, 1329 (Fed. Cir. 2005) and MPEP § 2111.”. The scope of claim 54, like that of claim 1, clearly encompasses polynucleotides both adsorbed and encapsulated by the microparticles. The applicant is directed to claims 46 and 50 in particular, which depend on claim 1, which specifically recite wherein a portion of the polynucleotide is entrapped within said microparticles. Thus, the scope of the claimed invention reads on microparticles which have polynucleotide absorbed to the surface and encapsulated within the particle. Further, the interaction of the polynucleotide with the

microparticle depends on the charge characteristics of the microparticle itself and the presence or absence of additional molecules such as detergents or surfactants. The microparticles taught by Hedley et al. are not positively charged, thus combining the microparticles with the polynucleotide results primarily in encapsulation. On the other hand, Fattal et al. clearly teaches that adding a cationic detergent to the biodegradable microparticles results in particles with a positive charge such that the majority of the negatively charged polynucleotide absorbs onto the cationic surface rather than encapsulating within. Fattal et al. provides a useful diagram of the interactions on page 139, Figure 1. Combining the teachings of Song et al., Hedley et al., and Fattal et al. would thus result in microparticles with primarily adsorbed polynucleotide on the surface of the particle. Motivation for combining the teachings of Fattal et al. with those of Song et al. and Hedley et al., rests in the teachings of Fattal et al. that inclusion of a cationic detergent in microparticles increases the amount of polynucleotide associated with the polymer particles and increases the uptake of the nucleic acid by phagocytosis/endocytosis.

The applicant further argues that the processes for preparing the microparticles of Hedley et al. and the cationic particles of Fattal et al. are non-analogous such that the skilled artisan would not draw inferences between the teachings of Song, Hedley and Fattal. Specifically, the applicant argues that although some ordinary artisans at the time of filing favored “..encapsulation based on the notion that the DNA would be protected from the destructive elements (e.g., nucleases) encountered in the biological milieu, and others favor[ed] adsorption based on the notion that the DNA would be protected from destructive elements (e.g., high shear stresses) encountered in the processing environment”, the ordinary artisan would not have looked to Fattal et al. since Hedley already taught by method which avoided an adverse affect on nucleic

acid integrity during the encapsulation process (see page 14 of the instant response). This argument is not persuasive since 1) both the techniques of Hedley et al. and Fattal et al. are clearly analogous as being drawn to the same purpose of particle-mediated transfection of cells with a polynucleotide, and 2) by applicant's own admission, the prior art teaches that both methods have their advantages such that the substitution of one method for another would represent nothing more than simple substitution of one known method for another with predictable results. See MPEP 2141 Rationale (b), and *KSR International Co. v. Teleflex Inc.* (KSR), 550 U.S. ___, 82 USPQ2d 1385 (2007). Further, as noted above, Fattal et al. provides specific motivation for utilizing their methodology over Hedley's by teaching that inclusion of a cationic detergent in microparticles increases the amount of polynucleotide associated with the polymer particles and increases the uptake of the nucleic acid by phagocytosis.

Next, the applicant argues that Fattal et al. teaches antisense oligonucleotide rather than plasmid DNA such there would be no reasonable expectation of success in making and using CTAB microparticles adsorbed with plasmid DNA to transfect dendritic cells resulting in the expression of an encoded protein. This is not agreed. Figure 1 of Fattal et al. clearly demonstrates the chemical interaction between the oligonucleotide and the cationic microparticle. According to Fattal et al., it is the negatively charged phosphate groups of the nucleic acid chain that form ion pairs with the hydrophobic cations on the surface of the biodegradable microparticles (Fattal et al., page 139, column 1). Regardless of whether the nucleic acid is an antisense oligonucleotide or nucleic acid present in a DNA plasmid, the nature of nucleic acids is that the backbone of the molecule is negatively charged. Thus, based on the nature of the negatively charged phosphate groups present in all nucleic acids, the skilled artisan

would have had reasonable expectation that negatively charged plasmid DNA would likewise form ion pairs with CTAB or another cationic detergent and would thus be capable of use in the microparticle/CTAB delivery vehicle taught by Fattal et al.. Applicant's argument that the skilled artisan would not have been motivated to absorb plasmid DNA to microparticles to enhance plasmid DNA delivery to the nucleus is further not found persuasive because the claims do not recite methods of enhancing DNA delivery to the nucleus. The claims recites methods of transfecting dendritic cells comprising incubating dendritic cells with the transfection agent leading to the expression of an antigen. Any degree of expression would meet the limitations of the claims as written. Thus, the references are not required to provide a motivation or a expectation of success for enhancing delivery of the plasmid to the cell nucleus. Fattal et al. was cited to provide motivation for including a cationic detergent in a composition comprising a microparticle and a polynucleotide. In fact, Fattal et al. provides clear motivation for including a cationic detergent in a microparticle by teaching that inclusion of a cationic detergent in microparticles increases the amount of polynucleotide associated with the polymer particles and increases the uptake of the nucleic acid by phagocytosis. Thus, the skilled artisan would have been amply motivated to include a cationic detergent in a microparticle composition comprising a polynucleotide encoding an antigen in order to increase uptake of the polynucleotide by the target cell with a reasonable expectation that such uptake would result in expression of an antigenic protein encoded by the polynucleotide.

Furthermore, regarding the expectation of success for expression of a protein encoded by a polynucleotide adsorbed onto a cationic microparticle, it is noted that the state of the art at the time of filing establishes that many different methods are useful for introducing expression

vectors into dendritic cells. The art further demonstrates that once in the cell, the vector expresses any encoded gene which is operably linked to appropriate expression elements, see for example Yang et al., Manickan et al., Spahn et al., and Tuting et al. (made of record by examiner) cited as rebuttal evidence to arguments/evidence presented by the applicants in the office action mailed on 12/18/03. Thus, the state of the art at the time of filing supports the conclusion of the Office that the skilled artisan would have had a reasonable expectation that transfection of dendritic cells with a CTAB microparticle containing adsorbed polynucleotide encoding an antigen would result in expression of the encoded antigen in the transfected cells. In addition, both Song et al. and Hedley et al. provide specific examples of gene expression after the uptake of expression vectors via different routes such as introduction by viruses, liposomes, and microparticles. As a result, the skilled artisan would reasonably expect that successful delivery of an expression vector into a cell would be followed by gene expression. Since Fattal et al. demonstrates the successful delivery of nucleic acid into cells using particles containing cationic detergents, the skilled artisan would therefore have had a reasonable expectation of success that delivery of expressible nucleic acids using the same technique would in fact result in gene expression. As such, applicant's arguments are not found persuasive.

Finally, the applicant argues that the skilled artisan would not be motivated to use cationic detergents with biodegradable microparticles because cationic detergents may impart stickiness to the resulting microparticles or have increased toxicity compared to nonionic detergents. However, since Fattal et al. actually teaches biodegradable microparticles with a cationic detergent and the successful use of the particles to deliver nucleic acid to cells, applicant's concerns about whether the skilled artisan would be motivated to combine a cationic

detergent and a microparticle are moot. Fattal et al. already teaches just that combination. In fact, as noted above, Fattal et al. provides clear motivation for including a cationic detergent in a microparticle by teaching that inclusion of a cationic detergent in microparticles increases the amount of polynucleotide associated with the polymer particles and increases the uptake of the nucleic acid by phagocytosis.

Therefore, for reasons of record as discussed in detail above, applicant's arguments have not been found persuasive in overcoming the rejection of claim 54.

2) The applicant argues that claims 1-16, 18-23, 29-31, 33-44, 46, 50, 52, and 53 are non-obvious over the cited references, for the same reasons that claim 54 was argued to be non-obvious. These arguments regarding the teachings of Song et al, Hedley et al., and Fattal et al. have been addressed in detail above in section **1)** in regards to independent claim 54, and were not found persuasive.

The applicant then reiterates the argument concerning the rejection of claim 1 and its dependent claims that unlike claim 54, claim 1 recites that the transfection agent is “..formed by a process that comprises: (a) providing microparticles comprising a biodegradable polymer and a cationic detergent, and (b) exposing said microparticles to said polynucleotide..” According to applicants, Fattal et al. does not teach adding polynucleotides to particles comprising a biodegradable polymer and the cationic detergent. The Office disagrees with applicant's description of the teachings of Fattal et al. On page 138, Fattal et al. clearly teaches that the oligonucleotide is added to a suspension comprising microparticles and CTAB (Fattal et al., page 138, column 2, paragraph 2). Due to the dynamic process of the association with cationic detergents the suspended microparticles, at least some portion of the particles taught by Fattal et

al. comprise CTAB before they further associate with the polynucleotide. Furthermore, it is noted that the limitation regarding the process by which the transfection agent is made is not set forth as actual method steps in the method of transfecting cells as claimed. Rather, the applicant has included a product by process limitation in their method of transfecting cells. As such, while the Office does find that Fattal et al. does in fact teach the referred to process for making the transfection agent used in the claimed methods, it can also be argued that the process used to prepare the transfection agent is irrelevant as the patentability of method of using the product does not depend on its method of production. Note that if a product in a product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” *In re Thorpe*, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) (citations omitted).

Therefore, for reasons of record as discussed in detail immediately above and in section 1), applicant’s arguments have not been found persuasive in overcoming the rejection of claims 1-16, 18-23, 29-31, 33-44, 46, 50, 52, and 53.

3) The applicant argues that claims 19-23 are non-obvious for all the same reasons that claim 54 and claims 1-16, 18-23, 29-31, 33-44, 46, 50, 52, and 53 are non-obvious, and further because in their opinion, none of Song et al., Hedley et al., or Fattal et al., teach the administration of dendritic cells that have been transfected *ex vivo* with the claimed transfection agent to a subject. In response, the arguments regarding the teachings of Song et al, Hedley et al., and Fattal et al. as they apply to claim 54 have been addressed in detail above in section 1) and in section 2) as they apply to the rejection of independent claim 1, and dependent claims 19-23.

These arguments were not found persuasive for reasons discussed in detail above.

The applicant then reiterates their argument that none of Song et al., Hedley et al., or Fattal et al., teach the administration of dendritic cells that have been transfected *ex vivo* with the claimed transfection agent to a subject, the applicant is directed to Song et al. As set forth in the rejection of record, Song et al. teaches methods of transfecting dendritic cells *ex vivo* or *in vitro* with a gene delivery vehicle comprising DNA encoding an antigen such as a tumor antigen, a viral antigen and specifically an HIV antigen, or an antigen derived from fungi, parasites, or bacteria, and use of said transfected dendritic cells to induce an immune response against the expressed antigen *in vivo* (Song et al., pages 2, 3, and 18-20). Song et al. teaches that the transfected dendritic cells can be administered to a vertebrate parenterally or by direct injection, (Song et al., pages 26 and 39). Thus, Song et al. provides the specific teachings to administer dendritic cells that have been transfected *ex vivo* to a subject for the purpose of inducing an immune response. Hedley et al. and Fattal et al. were cited for providing teachings and motivation to utilize a transfection agent comprising a polynucleotide adsorbed onto the surface of a microparticle comprising a biodegradable polymer and a cationic detergent over the cationic liposomes and plasmids or cationic lipids and plasmids taught by Song et al. Further, applicants contention that Song et al. expresses a clear preference for direct injection of recombinant retroviruses over *ex vivo* techniques, has already been addressed in section 1) above, which stated that although Song et al. may have exemplified retroviral transduction of dendritic cells, and stated a preference for the use of *in vivo* transfection of dendritic cells, neither of these teachings invalidates the clear teachings in this reference that many techniques, including non-viral techniques, can be used to transfect dendritic cells *in vitro*, or that the dendritic cells can be transfected *ex vivo* and then administered to the subject. It is reiterated that a reference must be

considered not only for what it expressly teaches, but also for what it fairly suggests. *In re Burkel*, 201 USPQ 67 (CCPA 1979). Further, the applicant is again directed to *In re Susi* and *In re Gurley*, which state respectively: that disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments. *In re Susi*, 440 F.2d 442, 169 USPQ 423 (CCPA 1971).

Therefore, for reasons of record as discussed in detail immediately above and in section **1) and 2)**, applicant's arguments have not been found persuasive in overcoming the rejection of claims 19-23.

In conclusion, the rejection of claims 1-9, 11-16, 18-23, 29-31, 33-44, 46, 50, and 52-54 under 35 U.S.C. 103(a) as being unpatentable over WO 97/24447 (7/10/97), hereafter referred to as Song et al., in view of US Patent No. 5,783,567 (7/21/98), hereafter referred to as Hedley et al., and further in view of Fattal et al. (1998) J. Controlled Rel., Vol. 53, 137-143, is maintained.

It is noted for the record that new claims 55-59 have not been added to the rejection of claims 1-9, 11-16, 18-23, 29-31, 33-44, 46, 50, and 52-54 under 35 U.S.C. 103(a) as being unpatentable over WO 97/24447 (7/10/97), hereafter referred to as Song et al., in view of US Patent No. 5,783,567 (7/21/98), hereafter referred to as Hedley et al., and further in view of Fattal et al. (1998) J. Controlled Rel., Vol. 53, 137-143 set forth above, because the new claims contain the negative limitation that polynucleotide is not entrapped within said microparticles. As noted above, claims 1-9, 11-16, 18-23, 29-31, 33-44, 46, 50, and 52-54 encompass microparticles where the polynucleotide is both adsorbed and encapsulated by the microparticle. While Fattal et al. teaches that the inclusion of cationic detergent in the microparticle results in

adsorption of oligonucleotides to nanoparticles, Fattal et al. does not teach or suggest that the inclusion of cationic detergent results in the complete exclusion of the nucleic acid from the interior of the particles. Further, since the method of making microparticles taught by Hedley et al. results in the majority of nucleic acid entrapped within the microparticle, it would not have been obvious to one of skill in the art to combine the teachings of Song et al., Hedley et al. and Fattal et al. to produce a microparticle in which polynucleotide encoding an antigen was exclusively adsorbed to the microparticle with no polynucleotide present entrapped within the microparticle.

Claim Objections

New claims 55-59 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

No claims are allowed at this time.

Any inquiry concerning this communication from the examiner should be directed to Anne Marie S. Wehbé, Ph.D., whose telephone number is (571) 272-0737. If the examiner is not available, the examiner's supervisor, Joseph Woitach, can be reached at (571) 272-0739. For all official communications, the technology center fax number is (571) 273-8300. Please note that all official communications and responses sent by fax must be directed to the technology center

fax number. For informal, non-official communications only, the examiner's direct fax number is (571) 273-0737. For any inquiry of a general nature, please call (571) 272-0547.

The applicant can also consult the USPTO's Patent Application Information Retrieval system (PAIR) on the internet for patent application status and history information, and for electronic images of applications. For questions or problems related to PAIR, please call the USPTO Patent Electronic Business Center (Patent EBC) toll free at 1-866-217-9197. Representatives are available daily from 6am to midnight (EST). When calling please have your application serial number or patent number available. For all other customer support, please call the USPTO call center (UCC) at 1-800-786-9199.

Dr. A.M.S. Wehbé

/Anne Marie S. Wehbé/
Primary Examiner, A.U. 1633